ORG 26041
Latest Information Update: 22 Jan 2010
At a glance
- Originator Organon
- Class
- Mechanism of Action Glycine transporter 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 19 Nov 2007 Organon has been acquired by Schering-Plough
- 30 Sep 2006 Phase-I clinical trials in Neurological disorders in USA (unspecified route)